The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index; 6 of the 93 sources its claims cite were checked for support.
The metabolic landscape of RAS-driven cancers from biology to therapy
Open accessAbstract
Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes metabolic dysregulation in cancer cells has advanced substantially over the last decade. In this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in cancer and elucidate the underlying mechanisms that could translate to novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers. Mukhopadhyay, Vander Heiden and McCormick review the metabolic landscape of RAS-driven cancers, the effects of RAS-directed metabolic reprogramming and opportunities for targeting these cancers therapeutically.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that oncogenic RAS, especially mutant KRAS, rewires glucose, glutamine, lipid, redox, and nutrient-scavenging metabolism to support tumor growth and therapy resistance. It surveys preclinical and early clinical strategies for exploiting these metabolic dependencies, while stressing that effective treatments will likely need to be context-specific and combinatorial.
Key findings
- RAS mutations contribute to roughly one third of human cancers, with KRAS predominant in many adenocarcinomas, NRAS prominent in melanoma and myeloid cancers, and HRAS mutated less often but mainly in bladder and head/neck squamous carcinoma. Mutation patterns vary by tissue: about 22% of oncogenic lung adenocarcinoma mutations are KRAS, while nearly 24% of skin cutaneous melanoma mutations are NRAS; G12C dominates in lung adenocarcinoma and G12D in pancreatic adenocarcinoma.
- Mutant KRAS increases glucose uptake and glycolytic flux through GLUT1, HK1/HK2, PFK1, ENO1, and LDHA, and also supports the hexosamine biosynthesis pathway and non-oxidative pentose phosphate pathway. KRAS4A can directly regulate HK1. Proposed glycolytic vulnerabilities include GAPDH inhibition by vitamin C, methylglyoxal scavengers combined with AKT inhibitors, and GLUT inhibitors such as silybin and BAY-876.
- KRAS-driven tumors often depend on glutaminolysis, the GOT1/2–ME1 pathway, NRF2-driven antioxidant programs, and xCT/cysteine metabolism; glutaminase inhibition may be especially relevant in tumors with KEAP1 or LKB1 co-mutations, and cysteine depletion can trigger ferroptosis. Lipid-related targets include ACLY, ACSL3, FASN, and fatty acid oxidation, while nutrient scavenging involves autophagy, NIX-mediated mitophagy, and macropinocytosis, with allele-specific differences such as KRAS G12R being impaired in PI3K signaling and macropinocytosis.
- Therapy resistance is linked to ROS management, stress granule formation via 15-d-PGJ2/NRF2, and compensatory signaling. KRAS G12C inhibitors show promise, but resistance suggests combinations with mTOR, SHP2, CDK4/6, or metabolic inhibitors; clinical trials are targeting glutaminolysis and autophagy.
Methods
- Narrative review, not a primary experimental study; it synthesizes literature on RAS biology and cancer metabolism, focusing mainly on KRAS and noting other isoforms where known.
- Mutation data for figures were compiled from AACR Genie Release 6.1-public, COSMIC v90, cBioPortal, TCGA, and NCI GDC; Figure 4 used previously published driver mutation data from ICGC/TCGA controlled access and an in-house pathway pattern extraction pipeline implemented in R.
- No systematic review, meta-analysis, or new experimental data are reported.
Limitations
- The authors state that many open questions remain: the interplay among KRAS isoforms, RAS alleles, tissue of origin, and metabolic alterations is poorly understood; whether RAS-mediated metabolic changes are common across all RAS-driven cancers is unanswered; and HRAS/NRAS metabolic landscapes are less explored.
- The authors note that metabolic flexibility and compensatory pathways can limit single-pathway targeting, that toxicity to normal cells and immune cells is a major concern, and that in vivo glutamine dependencies can differ from cell-culture findings, making model choice important.
- Evident from the text: as a review, it provides no primary validation or systematic search criteria, and many proposed metabolic therapies remain preclinical or early clinical and unapproved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
50 Not checked yet · 2 Supported · 2 Partly supported · 2 Own interpretation · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When mutated, oncogenic RAS remains preferentially in the active GTP-bound state, whereas GTP hydrolysis by its GTPase function and enzymes such as GTPase-activating proteins, is compromised1,2.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Introduction
What the sources say
- Partly supportedcites [1] Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017). sourceExperimental — accuracy not yet measured
The Cancer section says oncogenic RAS mutants are predominantly GTP-bound and that codon 12, 13, and 61 mutations resist GAP-mediated hydrolysis. It specifies that Q61 mutations impair both intrinsic and GAP-mediated hydrolysis, but the Direct Attack on RAS Proteins section says G12C retains relatively high intrinsic GTPase activity, similar to wild-type RAS. Thus the claim overgeneralizes impairment of intrinsic hydrolysis to oncogenic RAS mutations as a group; page numbers were not supplied in our copy. (LLM, conf=0.88)
- Supportedcites [2] Stalnecker, C. A. & Der, C. J. RAS, wanted dead or alive: advances in targeting RAS mutant cancers. Sci. Signal. https://doi.org/10.1126/scisignal.aay6013 (2020). source
The Introduction to RAS states that cancer-associated RAS mutations impair intrinsic and GAP-stimulated GTP hydrolysis, favoring formation of active RAS-GTP. This directly supports the cited sentence's general account. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“BAY-876, a potent GLUT1 inhibitor49, was separately shown as an effective candidate in pre-clinical setting 50.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Supportedcites [49] Siebeneicher, H. et al. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem 11, 2261–2271 (2016). source
Citation 49 is attached to the description of BAY-876 as a potent GLUT1 inhibitor, not to the separate preclinical-effectiveness statement cited to reference 50. The Results and Discussion describe BAY-876 as selected on the basis of GLUT inhibition, and the Conclusions call it a very selective GLUT1 inhibitor. This verdict does not assess the claim attached to reference 50. (LLM, conf=0.92)
- Supportedcites [50] Ma, Y. et al. Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876. Cancers https://doi.org/10.3390/cancers11010033 (2018). source
The Discussion reports that BAY-876 inhibited ovarian cancer cell proliferation and reduced tumor volumes and weights by 50–71% in cell-line and patient-derived xenograft models. It describes BAY-876 as a potent, selective GLUT1 inhibitor. These in vitro and animal findings support its characterization as an effective preclinical candidate, not as a clinically proven treatment. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, glycolytic KRAS-mutant cells produce increased amounts of potentially toxic byproducts of glycolysis such as methylglyoxal40.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Supportedcites [40] Bellier, J. et al. Methylglyoxal scavengers resensitize KRAS-mutated colorectal tumors to cetuximab. Cell Rep 30, 1400–1416 e1406 (2020). source
The Results section (p. 5) reports higher methylglyoxal levels in glycolytic KRAS G12V colorectal cancer cells than in isogenic KRAS wild-type cells. It also identifies methylglyoxal as a glycolysis byproduct using labeled-glucose experiments. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This could be explained by the fact that loss of LKB1 sustains KRAS-mediated proliferation through autophagy and increased synthesis of essential macromolecules, even under nutrient-deprived conditions68.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Partly supportedcites [68] Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science https://doi.org/10.1126/science.aaw5473 (2020). sourceExperimental — accuracy not yet measured
The Primary invasive cancers section (page not provided) says that LKB1 normally restrains anabolism during energetic stress and that combined KRAS–STK11 mutations are associated with aggressive tumors and altered metabolism. It also discusses continued proliferation under nutrient deprivation, but does not link that outcome specifically to LKB1 loss through autophagy and increased macromolecule synthesis. (LLM, conf=0.86)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Analysis of data from the PanCancer Analysis of Whole Genomes Consortium samples135 on the KEGG pathway database137 depicts oncogenic driver genes involved in various metabolism processes in many cancer tissue types (Fig. 4a)”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Targeting oncogenic RAS-related metabolism > Connecting RAS to other oncogenic drivers and metabolic pathways
What the sources say
- Not checked yetcites [135] ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020). source
- Not checked yetcites [137] Alam, H. et al. KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer Cell 37, 599–617 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“with a gene-level analysis of each corresponding pathway unveiling driver genes that are co-altered in diverse tissue types (Fig. 4b).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Targeting oncogenic RAS-related metabolism > Connecting RAS to other oncogenic drivers and metabolic pathways
What the sources say
- Not checked yetcites [135] ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020). source
- Not checked yetcites [137] Alam, H. et al. KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer Cell 37, 599–617 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Targeting oncogenic RAS-related metabolism > Connecting RAS to other oncogenic drivers and metabolic pathways
What the sources say
- Not checked yetcites [138] Castellano, E. & Downward, J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2, 261–274 (2011). source
- Not checked yetcites [139] Nogueira, C. et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 6222–6232 (2010). source
- Not checked yetcites [140] Wakimoto, H. et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin. Cancer Res. 20, 2898–2909 (2014). source
- Not checked yetcites [141] Fernandez-Garcia, B. et al. p73 cooperates with Ras in the activation of MAP kinase signaling cascade. Cell Death Differ. 14, 254–265 (2007). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“KRAS also promotes the hexosamine biosynthesis pathway (HBP), which provides precursors for lipid and protein glycosylation34, and the non-oxidative arm of the pentose phosphate pathway (PPP)28, which supplies ribose, the backbone for nucleic acid production35 (Fig 2).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [34] Slawson, C., Copeland, R. J. & Hart, G. W. O-GlcNAc signaling: a metabolic link between diabetes and cancer? Trends Biochem. Sci. 35, 547–555 (2010). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The breakdown of glutamine through glutaminolysis gives rise to glutamate, a critical precursor of most other nonessential amino acids, including aspartate, alanine, arginine, and proline52.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [52] Yang, L., Venneti, S. & Nagrath, D. Glutaminolysis: a hallmark of cancer metabolism. Annu. Rev. Biomed. Eng. 19, 163–194 (2017). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Introduction
What the sources say
- Not checked yetcites [3] Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 1
None of the sources cited for this claim have been checked yet.
In the paper
“KRAS in particular, is among the most frequently mutated oncogenes in cancer and is commonly associated with therapeutic resistance and poor prognosis1,5,6.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Introduction
What the sources say
- Not checked yetcites [1] Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017). source
- Not checked yetcites [5] Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013). source
- Not checked yetcites [6] Haigis, K. M. KRAS alleles: the devil is in the detail. Trends Cancer 3, 686–697 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Furthermore, the tumor suppressor LKB1, which activates the energy sensor and metabolic regulator AMPK, has been linked to serine metabolism and induction of tumorigenesis45.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [45] Kottakis, F. et al. LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature 539, 390–395 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, the initial enthusiasm has been somewhat tempered by work suggesting that acquired resistance may constrain the inhibitors’ efficacy, which indicates that combination therapies may be needed11–14.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Introduction
What the sources say
- Not checked yetcites [11] Hata, A. N. & Shaw, A. T. Resistance looms for KRASG12C inhibitors. Nat. Med. 26, 169–170 (2020). source
- Not checked yetcites [12] Bar-Sagi, D., Knelson, E. H. & Sequist, L. V. A bright future for KRAS inhibitors. Nat. Cancer 1, 25–27 (2020). source
- Not checked yetcites [13] Fedele, C. et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J. Exp. Med. https://doi.org/10.1084/jem.20201414 (2021). source
- Not checked yetcites [14] Ryan, M. B. et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin. Cancer Res. 26, 1633–1643 (2020). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additionally, oncogenic HRAS mediates enhanced glycolytic rates including increased glucose uptake, underscoring the fact that increased aerobic glycolysis is essential for RAS-mutant tumors to match energy production with the requirement for enhanced biosynthetic pathways39.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [39] Lock, R. et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol. Biol. Cell 22, 165–178 (2011). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The recognition that oncogenes, including RAS, can promote aerobic glycolysis, commonly known as the Warburg effect, and activate anabolic pathways 22,23, has increased efforts to understand the molecular underpinnings of altered metabolism in cancer24.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism
What the sources say
- Not checked yetcites [22] Nagarajan, A., Malvi, P. & Wajapeyee, N. Oncogene-directed alterations in cancer cell metabolism. Trends Cancer 2, 365–377 (2016). source
- Not checked yetcites [23] Levine, A. J. & Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340–1344 (2010). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A promising candidate is silybin, a natural flavonoid and potent inhibitor of GLUT1 and GLUT4, which was shown to be effective in phase 1 trial of prostate cancer with asymptotic liver toxicity as an adverse effect48.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [48] Flaig, T. W. et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs 25, 139–146 (2007). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Oncogenic KRAS also upregulates expression of other key glycolytic enzymes, such as PFK1, ENO1, and LDHA28,31–33, thereby promoting glycolytic flux and enabling the production of glycolytic intermediates that can be shunted into other anabolic pathways (Fig 2).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [28] Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012). source
- Not checked yetcites [31] Kole, H. K., Resnick, R. J., Van Doren, M. & Racker, E. Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. Arch. Biochem. Biophys. 286, 586–590 (1991). source
- Not checked yetcites [32] Racker, E., Resnick, R. J. & Feldman, R. Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. Proc. Natl Acad. Sci. USA 82, 3535–3538 (1985). source
- Not checked yetcites [33] Chun, S. Y. et al. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes. Mol. Cancer 9, 293 (2010). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Of note, LKB1 loss is prevalent in KRAS mutant lung cancers46, indicating that oncogenic KRAS not only induces mTOR activity, but might also upregulate one-carbon metabolism by undermining AMPK’s inhibitory role in the folate cycle.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [46] Calles, A. et al. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS-mutant lung adenocarcinoma. Clin. Cancer Res. 21, 2851–2860 (2015). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Mutant KRAS has also been implicated in the induction of enzymes involved in the folate cycle42 and the aberrant activation of mTOR, a key regulator for both serine synthesis and the folate cycle43,44.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [42] Moran, D. M. et al. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. Mol. Cancer Ther. 13, 1611–1624 (2014). source
- Not checked yetcites [43] Gomes, A. P. & Blenis, J. A nexus for cellular homeostasis: the interplay between metabolic and signal transduction pathways. Curr. Opin. Biotechnol. 34, 110–117 (2015). source
- Not checked yetcites [44] Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J. H., Asara, J. M. & Manning, B. D. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351, 728–733 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overall, KRAS is mutated in many cancers (predominantly adenocarcinomas), whereas NRAS mutations are prominent in melanoma and myeloid cancer4,15,16 (Fig. 1).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS mutations in cancer
What the sources say
- Not checked yetcites [4] Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457–2467 (2012). source
- Not checked yetcites [15] Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of Ras mutations in cancer. Cancer Res. 80, 2969–2974 (2020). source
- Not checked yetcites [16] Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 19, 533–552 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consequently, treatment efficacy cannot be extrapolated from one RAS-driven cancer to another, but rather therapeutic approaches must be tailored to the isoform, mutation and tissue.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS mutations in cancer
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For instance, 22% of oncogenic mutations in lung adenocarcinoma (LUAD) occur in KRAS, whereas nearly 24% of such mutations in skin cutaneous melanoma occur in NRAS15 (Fig. 1b).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS mutations in cancer
What the sources say
- Not checked yetcites [15] Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of Ras mutations in cancer. Cancer Res. 80, 2969–2974 (2020). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Highly glycolytic RAS-mutant cells have been found to be vulnerable to inhibition of the glycolytic enzymes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with Vitamin C, providing a mechanistic rationale for exploring the therapeutic use of this vitamin against KRAS or BRAF mutant colorectal cancer preclinical models 38.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [38] Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391–1396 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, RAS mutations and the resulting deregulated signaling events are responsible for one third of all human cancers4 (Figure 1).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Introduction
What the sources say
- Not checked yetcites [4] Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457–2467 (2012). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Gene expression and metabolic flux analyses have shown that it upregulates the expression of the GLUT1 glucose transporter to promote glucose uptake by cells, as well as inducing expression of hexokinase 1 and 2 (HK1 and HK2) rate-limiting enzymes of glycolysis, to increase glycolytic activity27–30 (Fig. 2a).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [27] Gaglio, D. et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011). source
- Not checked yetcites [28] Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012). source
- Not checked yetcites [29] Amendola, C. R. et al. KRAS4A directly regulates hexokinase 1. Nature 576, 482–486 (2019). source
- Not checked yetcites [30] Yun, J. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555–1559 (2009). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Methylglyoxal-mediated stress was shown to be involved in cancer progression41 and to be a potent activator of AKT signaling, suggesting that utilizing methylglyoxal scavengers in KRAS mutant colorectal cancer cells might be more effective when combined with AKT inhibitors40.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [40] Bellier, J. et al. Methylglyoxal scavengers resensitize KRAS-mutated colorectal tumors to cetuximab. Cell Rep 30, 1400–1416 e1406 (2020). source
- Not checked yetcites [41] Bellahcene, A., Nokin, M. J., Castronovo, V. & Schalkwijk, C. Methylglyoxal-derived stress: an emerging biological factor involved in the onset and progression of cancer. Semin. Cancer Biol. 49, 64–74 (2018). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“KRAS regulates these pathways through MAPK-dependent signaling cascades, ultimately supporting cell survival and conferring a proliferative advantage on tumors28,36,37.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Interplay between oncogenic RAS and glucose metabolism
What the sources say
- Not checked yetcites [28] Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012). source
- Not checked yetcites [36] Taparra, K. et al. O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. J. Clin. Invest. 128, 4924–4937 (2018). source
- Not checked yetcites [37] Santana-Codina, N. et al. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat. Commun. 9, 4945 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Limiting glutamine use combined with chemotherapy is a viable means to halt pancreatic tumor growth in preclinical mouse models and is not toxic to normal cells58,60,65.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [58] Mukhopadhyay, S., Saqcena, M. & Foster, D. A. Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. Oncoscience 2, 807–808 (2015). source
- Not checked yetcites [60] Mukhopadhyay, S. et al. Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-19-1363 (2020). source
- Not checked yetcites [65] Saqcena, M. et al. Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene 34, 2672–2680 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Cells from advanced lung tumors with oncogenic KRAS and loss-of-function KEAP1 mutations were more dependent on increased amounts of glutamine than other cells, making them more susceptible to glutaminase inhibition62.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [62] Romero, R. et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat. Med. 23, 1362–1368 (2017). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition to activating the GOT2/GOT1/Malic Enzyme 1 (ME1) pathway, oncogenic KRAS activates the NRF2 antioxidant system by inducing NRF2 expression59,60 and by constitutively activating the battery of genes controlled by NRF2 to maintain the redox balance and promote tumorigenesis61.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [59] DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109 (2011). source
- Not checked yetcites [60] Mukhopadhyay, S. et al. Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-19-1363 (2020). source
- Not checked yetcites [61] Chio, I. I. C. et al. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166, 963–976 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Moreover, KRAS-driven lung adenocarcinomas with TP53 mutation induce immune cell production, while tumors with KEAP1 mutations rewire metabolism71.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [71] Best, S. A. et al. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat. Commun. 10, 4190 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Concurrent mutations in KRAS and LKB1 also confer vulnerabilities in pancreatic cancer, but the mechanisms are different from those in lung cancer45.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [45] Kottakis, F. et al. LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature 539, 390–395 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Co-occurrence of mutant KRAS and LKB1 deficiency in patients with lung cancer resulted in more aggressive tumors, higher frequency of metastasis, and therapy resistance67.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [67] Skoulidis, F. & Heymach, J. V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat. Rev. Cancer 19, 495–509 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, KRAS has also been shown to promote cancer cell growth by stimulating alanine aminotransferase activity, leading to high levels of α-ketoglutarate for the TCA cycle and mitochondrial ROS generation, which was required for mutant KRAS-driven tumorigenesis in a mouse model of lung cancer64.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [64] Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788–8793 (2010). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several oncogenes coordinate the transcriptional reprogramming that tumor cells need to thrive, with many cancer driver genes also perturbing metabolism135,136.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > Targeting oncogenic RAS-related metabolism > Connecting RAS to other oncogenic drivers and metabolic pathways
What the sources say
- Not checked yetcites [135] ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020). source
- Not checked yetcites [136] Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. & Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355–D360 (2010). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For instance, KRAS-dependent upregulation of Glutamate Oxaloacetate Transaminase 1,2. (GOT) expression in pancreatic cancer facilitates production of aspartate for nucleotide biosynthesis, and allows NADPH generation via ME157,58 (Fig 2).”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [57] Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013). source
- Not checked yetcites [58] Mukhopadhyay, S., Saqcena, M. & Foster, D. A. Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. Oncoscience 2, 807–808 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Moreover, in oncogenic-KRAS-driven lung adenocarcinoma, loss of LKB1 often induces KEAP1 activation69 and leads to metabolic alterations that could be counteracted by activation of NRF270, thereby maintaining redox homeostasis and fueling energy metabolism in a glutamine-dependent manner.”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
What the sources say
- Not checked yetcites [69] Kaufman, J. M. et al. LKB1 loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K–AKT. J. Thorac. Oncol. 9, 794–804 (2014). source
- Not checked yetcites [70] Li, F. et al. LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. Cancer Cell 27, 698–711 (2015). source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Metabolic changes caused by oncogenes can be broad, with several pathways altered at once within one cancer type.
“Oncogene-directed metabolic alterations can have extensive impact, with multiple metabolic pathways being altered simultaneously in a single cancer type.”
The paper relies on this without support.
Metabolic phenotypes differ between tumor types and also vary among tumors of the same type.
“The elucidation of these events should also take into account the fact that metabolic phenotype is not uniform across different tumor types, and variability also exists between different tumors of the same type.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, glutaminase inhibitors and agents targeting aspartate metabolism, such as ASS1 inhibitors, may enhance the efficacy of KRAS inhibitors in colorectal cancer [33,35].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“STK11 is also a critical regulator of metabolism via its substrate AMPK (73).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [73]
In the citing paper
“Oncogenic KRAS significantly reprograms cellular metabolism, enhancing glycolysis, glutaminolysis, and aspartate metabolism to fuel tumor growth and survival.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [33]
In the citing paper
“KRAS mutations drive the upregulation of key enzymes, such as PCK1, PCK2, and ASS1, which are involved in aspartate and urea cycle metabolism, contributing to the metabolic flexibility of KRAS-mutant CRC cells [33,34,35].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [33]
In the citing paper
“Targeting these pathways has shown promise in preclinical studies.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
“xCT, the cystine/glutamate antiporter that exports glutamate to the extracellular space and imports cysteine into the cytosol for the production of the amino acid cysteine”
§ The Metabolic Landscape of RAS-Driven Cancers from biology to therapy > RAS and tumor metabolism > Oncogenic RAS in glutaminolysis and redox homeostasis
“Cystine import is key to KRAS-driven PDAC cell survival”
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Cited by
Sorted by citations
Items 101–200 of 326
Castelli, S., Ciccarone, F., Falco, P. D., & Ciriolo, M. R. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216010 · Cited by 20
Liu, X., Hu, Y., Xue, Z., Zhang, X., Liu, X., Liu, G., Wen, M., Chen, A., Huang, B., Li, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03984-0 · Cited by 20
Ohguro, H., Watanabe, M., Sato, T., Hikage, F., Furuhashi, M., Okura, M., Hida, T., & Uhara, H. (2023) · Cells · doi:10.3390/cells12050759 · Cited by 20
Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
Lee, J. J., Jain, V., & Amaravadi, R. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212402 · Cited by 20
Targeting macropinocytosis for cancer therapy
Tang, D., Wang, J., Kroemer, G., & Kang, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00892-x · Cited by 26
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Lam, K. K., Wong, S. H., & Cheah, P. Y. (2023) · Cells · doi:10.3390/cells12040631 · Cited by 19
Chitosan based nanocarriers as a promising tool in treatment and management of inflammatory diseases
Goyal, S., Thirumal, D., Rana, J., Gupta, A. K., Kumar, A., Babu, M. A., Kumar, P., & Sindhu, R. K. (2024) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2024.100442 · Cited by 22
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 20
Cancer network pharmacology: multi-network regulatory mechanisms and future directions
Zhao, Z., Le, J., Fu, Z., Yang, S., & Chen, Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02811-4 · Cited by 20
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 19
Erk1/2-Dependent HNSCC Cell Susceptibility to Erastin-Induced Ferroptosis
Savic, D., Steinbichler, T. B., Ingruber, J., Negro, G., Aschenbrenner, B., Riechelmann, H., Ganswindt, U., Skvortsov, S., Dudás, J., & Skvortsova, I. (2023) · Cells · doi:10.3390/cells12020336 · Cited by 18
Yang, T., Chen, W., Gan, K., Wang, C., Xie, X., Su, Y., Lian, H., Xu, J., Zhao, J., & Liu, Q. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04706-2 · Cited by 17
The RAS oncogene in brain tumors and the involvement of let-7 microRNA
Messina, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09439-z · Cited by 22
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 18
Ma, J., Fu, S., Tan, J., Han, Y., Chen, Y., Deng, X., Shen, H., Zeng, S., Peng, Y., & Cai, C. (2025) · Advanced Science · doi:10.1002/advs.202502714 · Cited by 17
Current Pathology Model of Pancreatic Cancer
Szymoński, K., Milian-Ciesielska, K., Lipiec, E. W., & Adamek, D. (2022) · Cancers · doi:10.3390/cancers14092321 · Cited by 15
Site-Specific Activity-Based Protein Profiling Using Phosphonate Handles
van Bergen, W., Hevler, J. F., Wu, W., Baggelaar, M. P., & Heck, A. J. R. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100455 · Cited by 16
Bildik, G., Gray, J. P., Mao, W., Yang, H., Özyurt, R., Orellana, V. R., Wever, O. D., Carey, M. S., Bast, R. C., & Lü, Z. (2024) · Autophagy · doi:10.1080/15548627.2023.2299516 · Cited by 16
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Tenekeci, A. K., Unal, A. A., Ceylan, F., & Sendur, M. A. N. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407280 · Cited by 16
Past and Future Strategies to Inhibit Membrane Localization of the KRAS Oncogene
Haidar, M., & Jacquemin, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413193 · Cited by 18
Raising the iron curtain: Lactate's secret role in oxidative stress defense
Hensel, A., Váraljai, R., & Knauer, S. K. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103754 · Cited by 16
Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers
Moss, D., McCann, C. K., & Kerr, E. M. (2022) · Science Signaling · doi:10.1126/scisignal.abj3490 · Cited by 16
Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer
Lo, A., McSharry, M. V., & Berger, A. H. (2022) · BMC Cancer · doi:10.1186/s12885-022-10311-1 · Cited by 16
Shetu, S. A., James, N., Rivera, G., & Bandyopadhyay, D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030124 · Cited by 15
Regulation of Ras Signaling by S-Nitrosylation
Simão, S., Agostinho, R. R., Martı́nez-Ruiz, A., & Araújo, I. M. (2023) · Antioxidants · doi:10.3390/antiox12081562 · Cited by 15
PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma
Gaballa, A., Gebhardt-Wolf, A., Krenz, B., Mattavelli, G., John, M., Cossa, G., Andreani, S., Schülein‐Völk, C., Montesinos, F., Vidal, R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45760-8 · Cited by 14
Yu, F., Gajendran, B., Wang, N., Sample, K. M., Liu, W., Wang, C., Hu, A., Zacksenhaus, E., Hao, X., & Ben‐David, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08402-6 · Cited by 14
Arginine Regulates TOR Signaling Pathway through SLC38A9 in Abalone Haliotis discus hannai
Liu, Y., Yu, H., Guo, Y., Huang, D., Liu, J., Pan, M., Wang, L., Zhang, W., & Mai, K. (2021) · Cells · doi:10.3390/cells10102552 · Cited by 15
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 17
Glycolysis Dependency as a Hallmark of SF3B1-Mutated Cells
Vivet-Noguer, R., Tarin, M., Canbezdi, C., Dayot, S., Silva, L. E., Houy, A., Martineau, S., Mieulet, V., Gentric, G., Loew, D., et al. (2022) · Cancers · doi:10.3390/cancers14092113 · Cited by 13
Huang, Y., Chen, Y., Zhou, S., Xie, L., Liang, K., Xu, J., Zhang, Q., Chen, H., Wang, D., Song, Q., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04069 · Cited by 13
Guo, T., Wu, C., Zhou, L., Zhang, J., Wang, W., Shen, Y., Zhang, L., Niu, M., Zhang, X., Yu, R., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04332-y · Cited by 13
Hatipoglu, A., Menon, D., Levy, T., Frías, M. A., & Foster, D. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276579 · Cited by 13
Targeting autophagy drug discovery: Targets, indications and development trends
Jiang, M., Wu, W., Xiong, Z., Ye, Z., Ye, Z., & Wu, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116117 · Cited by 13
EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer
Krauß, D., Moreno‐Viedma, V., Adachi-Fernandez, E., Fernandes, C. D. S., Genger, J., Fari, O., Blauensteiner, B., Kirchhofer, D., Bradaric, N., Gushchina, V., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00240-4 · Cited by 13
Fan, H., Chen, H., Song, H., Li, C., Wang, Y., Zhao, Z., Guo, Q., Li, X., Liu, M., Sun, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202507118 · Cited by 13
Synthetic Vulnerabilities in the KRAS Pathway
Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 14
Wei, Z., Lin, X., Wang, S., Zhang, J., Ji, D., Gong, X., Huang, Z., Shu, B., & Li, D. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106526 · Cited by 12
Tanaka, I., Koyama, J., Itoigawa, H., Hayai, S., & Morise, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249237 · Cited by 13
Saraf, P., Bhardwaj, B., Verma, A., Siddiqui, M. A., Verma, H., Kumar, P., Srivastava, S., Krishnamurthy, S., Srikrishna, S., & Shrivastava, S. K. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00471j · Cited by 12
Xu, C., Lin, W., Zhang, Q., Ma, Y., Wang, X., Guo, A., Zhou, Z., Zhou, Z., Song, W., Zhao, Z., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00972-y · Cited by 13
Richards, C. E., Elamin, Y. Y., Carr, A., Gately, K. A., Rafee, S., Cremona, M., Hanrahan, E. O., Smyth, R., Ryan, D., Morgan, R. K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310545 · Cited by 13
RetractedA novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma
Wen, J., Zhao, W., & Shu, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1087762 · Cited by 12
A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer
Ruff, S. M., & Pawlik, T. M. (2023) · Cancers · doi:10.3390/cancers15051395 · Cited by 12
Glucose metabolism reprogramming promotes immune escape of hepatocellular carcinoma cells
Zhang, Q., Liu, J., Lin, H., Lin, B., Zhu, M., & Li, M. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00149 · Cited by 11
Yang, H., Wang, J., Zhou, X., Fu, D., Le, C., Wei, J., Qian, Y., Fang, Y., Jin, T., Kong, X., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102307 · Cited by 12
Okuno, K., Xu, C., Pascual-Sabater, S., Tokunaga, M., Takayama, T., Han, H., Fillat, C., Kinugasa, Y., & Goel, A. (2023) · Biomedicines · doi:10.3390/biomedicines11010119 · Cited by 12
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
Lakhani, A., Kang, D. H., Kang, Y. E., & Park, J. O. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1814 · Cited by 11
Growth Signaling Networks Orchestrate Cancer Metabolic NetworksPreprint
Manning, B. D., & Dibble, C. C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041543 · Cited by 11
Zhang, Y., Jin, S., Zuo, Z., Liu, S., Xu, J., Yang, C., Wan, P., Xun, L., Luo, M., Yang, F., et al. (2025) · Vaccines · doi:10.3390/vaccines13060563 · Cited by 10
Xu, R., Zhao, M., Yang, Y., Han, X., Ren, X., Liu, G., Wang, H., Liang, J., Tong, A., Peng, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c03547 · Cited by 10
Zerbato, B., Gobbi, M., Ludwig, T., Brancato, V., Pessina, A., Brambilla, L., Wegner, A., & Chiaradonna, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1125855 · Cited by 10
New insights into RAS in head and neck cancer
Jagadeeshan, S., Novoplansky, O., Cohen, O. M., Kurth, I., Heß, J., Rosenberg, A. J., Grandis, J. R., & Elkabets, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188963 · Cited by 11
Liu, M. R., Wu, S., Wu, H., Zhou, Y., Zhang, X., Zhu, D., & Jiang, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05277-6 · Cited by 9
Wei, P., Jia, H., Li, R., Zhang, C., Guo, S., Wei, S., Sun, K., Cheng, S., Cui, T., Huang, J., et al. (2022) · Cell Biology International · doi:10.1002/cbin.11936 · Cited by 9
Rahman, M., Nguyen, T. M., Lee, G. J., Kim, B., Park, M. K., & Lee, C. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031489 · Cited by 7
Maietta, I., Viscusi, E., Laudati, S., Iannaci, G., D’Antonio, A., Melillo, R. M., Motti, M. L., & Falco, V. D. (2024) · Cells · doi:10.3390/cells13181546 · Cited by 8
Whole-exome sequencing identifies distinct genomic aberrations in eccrine porocarcinomas and poromas
Puttonen, M., Almusa, H., Böhling, T., Koljonen, V., & Sihto, H. J. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03586-7 · Cited by 9
Bian, Y., Shan, G., Bi, G., Xu, Z., Liang, J., Yan, Y., Guo, W., Sui, Q., Yi, Y., Shi, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65441-4 · Cited by 11
Leiphrakpam, P. D., Batra, R., Tenner, L. L., & Are, C. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl39100 · Cited by 10
KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020873 · Cited by 8
KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player
Trassl, L., & Stathopoulos, G. T. (2022) · Cancers · doi:10.3390/cancers14174303 · Cited by 8
Development of a high-throughput TR-FRET screening assay for a fast-cycling KRAS mutant
Larson, J. E., Hardy, P. B., Schomburg, N. K., Wang, X., Kireev, D., Rossman, K. L., & Pearce, K. H. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.12.001 · Cited by 9
A pan-cancer analysis implicates human NKIRAS1 as a tumor-suppressor gene
Postler, T. S., Wang, A., Brundu, F. G., Wang, P., Wu, Z., Butler, K. E., Grinberg‐Bleyer, Y., Krishnareddy, S., Lagana, S. M., Saqi, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312595120 · Cited by 8
Balakrishnan, K., Chen, Y., & Dong, J. (2024) · Cancers · doi:10.3390/cancers16091781 · Cited by 8
Zhu, Y., An, N., Zhang, Q., Liu, Y., Gu, P., Zhao, J., Pan, W., Pu, Q., & Zhu, W. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00928-2 · Cited by 7
Lactylation and acetylation: parallel paths, divergent deeds, and research dilemmas
Jiang, W., Chen, Y., Lin, S., Liu, Y., & Liao, X. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07877-w · Cited by 8
Cuyàs, E., Fernández‐Arroyo, S., Verdura, S., Lupu, R., Joven, J., & Menéndez, J. A. (2022) · Cancers · doi:10.3390/cancers14246214 · Cited by 7
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors
Kareff, S. A., Trabolsi, A., Krause, H. B., Samec, T., Elliott, A., Rodríguez, E., Olazagasti, C., Watson, D. C., Bustos, M. A., Hoon, D. S. �., et al. (2024) · Cancers · doi:10.3390/cancers16081572 · Cited by 7
Zheng, M., Qu, J., Xiang, D., & Xing, L. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189235 · Cited by 9
Duan, X., Qin, W., Hao, J., Wang, J., Qiu, Y., Shentu, X., Ye, Z., & Yu, X. (2024) · Talanta · doi:10.1016/j.talanta.2024.127287 · Cited by 6
Chen, R., Hao, X., Chen, J., Zhang, C., Fan, H., Lian, F., Chen, X., Wang, C., & Xia, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04400-3 · Cited by 6
Ezzat, R. S. (2024) · American Journal of Cancer Research · doi:10.62347/foyi6658 · Cited by 6
Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
Río-Vilariño, A., del Puerto‐Nevado, L., García‐Foncillas, J., & Cebrián, A. (2021) · Cancers · doi:10.3390/cancers13153757 · Cited by 6
Schnipper, J., Kouba, S., Hague, F., Girault, A., Telliez, M., Guénin, S., Ahidouch, A., Pedersen, S. F., & Ouadid‐Ahidouch, H. (2022) · Cancers · doi:10.3390/cancers14194946 · Cited by 6
Silverman, I., Gerber, M. A., Shaykevich, A., Stein, Y. F., Siegman, A., Goel, S., & Maitra, R. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1436976 · Cited by 7
Insights into RAS-driven melanoma and its therapeutic implications
Chatziioannou, E., Lallas, K., Sinnberg, T. W., Niessner, H., Stratigos, A., Flatz, L., & Amaral, T. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103090 · Cited by 5
In Silico Identification of Dysregulated miRNAs Targeting KRAS Gene in Pancreatic Cancer
Garibaldi-Ríos, A. F., Figuera, L. E., Zúñiga‐González, G. M., Gómez‐Meda, B. C., García-Verdín, P. M., Carrillo-Dávila, I. A., Gutiérrez-Hurtado, I. A., Torres-Mendoza, B. M., & Gallegos‐Arreola, M. P. (2024) · Diseases · doi:10.3390/diseases12070152 · Cited by 5
Current hotspots and trends in cancer metabolic reprogramming: a scientometric analysis
Yang, S., Lin, M., Hao, S., Ye, H., & Zhang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1497461 · Cited by 5
Yasue, S., Ozeki, M., Nozawa, A., Endo, S., & Ohnishi, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0289187 · Cited by 5
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
Dekker, S. E., & Deng, L. (2024) · Cancers · doi:10.3390/cancers16223885 · Cited by 5
Serine-Driven Metabolic Plasticity Drives Adaptive Resilience in Pancreatic Cancer Cells
Bonanomi, M., Mallia, S., Scalise, M., Aramini, T., Baldassari, F., Brivio, E., Conte, F., Dico, A. L., Bonas, M., Porro, D., et al. (2025) · Antioxidants · doi:10.3390/antiox14070833 · Cited by 4
Cuprych, M., Łupicka‐Słowik, A., Anisiewicz, A., Michaelis, M., Cinatl, J. J., & Psurski, M. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.95 · Cited by 4
Jia, A., Zhang, X., Zhou, J., Ma, Y., Wang, J., Gong, Y., Song, W., Hu, H., Yu, Y., Yang, H., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.01.001 · Cited by 4
The Target Therapy Hyperbole: “KRAS (p.G12C)”—The Simplification of a Complex Biological Problem
Chetta, M., Basile, A., Tarsitano, M., Rivieccio, M., Oro, M., Capitanio, N., Bukvić, N., Priolo, M., & Rosati, A. (2024) · Cancers · doi:10.3390/cancers16132389 · Cited by 4
Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma
Shah, A., Johnson, E., Ponnusamy, M. P., & Batra, S. K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2507035 · Cited by 4
Wadding-Lee, C., & Makarewich, C. A. (2025) · Cells · doi:10.3390/cells14120859 · Cited by 5
Zaczek, A., Szustka, A., & Krześlak, A. (2022) · Cancers · doi:10.3390/cancers14235947 · Cited by 4
Xiao, Y., Zhu, Y., Chen, J., Wu, M., Wang, L., Su, L., Feng, F., & Hou, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-00997-z · Cited by 4
Desai, A. P., Xiao, A. H., Choi, D., Toruner, M. D., Walden, D. M., Halfdanarson, T. R., Alberts, S. R., McWilliams, R. R., Mahipal, A., Ahn, D. H., et al. (2024) · Cancers · doi:10.3390/cancers16101861 · Cited by 4
Jia, M., Feng, S., Cao, F., Deng, J., Li, W., Zhou, W.-Y., Liu, X., & Bai, W. (2022) · Cancers · doi:10.3390/cancers14205073 · Cited by 4
Kumar, P., Kumar, R. C., Kumar, P., Kushwaha, S., Kumari, S., Yadav, N., & Srikrishna, S. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00502 · Cited by 3
Molecular Imaging: Unveiling Metabolic Abnormalities in Pancreatic Cancer
Wang, H., Gui, Y., & Lv, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115242 · Cited by 3
Zhang, T., Han, H., Zhang, T., Zhang, Y., Ma, L., Yang, Z. R., & Zhao, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189459 · Cited by 4
Zheng, B., Chen, Z.-X., Wang, Y.-K., Dong, J.-P., She, M., Zheng, Y., Zeng, Y.-X., Zheng, W.-D., Long, W. S., & Wong, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03088 · Cited by 4
Rekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 3
Ma, L., Zhang, X., Liu, Y., Jin, H., Li, D. X., Zhang, H., Feng, L., Zuo, J., Wang, Y., Liu, J., et al. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-154 · Cited by 3
Cheng, B., Liu, J., Gao, L., Zhu, Z., Yang, Y., Liu, S., & Wu, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06290-z · Cited by 3
Pan-Cancer Analysis Identifies a Ras-Related GTPase as a Potential Modulator of Cancer
Hsueh, H., Gumpper, K., Poelstra, J. W., Pitter, K. L., & Cruz‐Monserrate, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094419 · Cited by 3
Karra, L., Finger, A., Shechtman, L. A., Krush, M., Huang, M., Prinz, M., Tenvooren, I., Bahl, K., Hysienaj, L., García-González, P. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014411 · Cited by 4
Metadata
- Authors
- Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F.
- Affiliations
- NYU Langone Health (US)
- University of California, San Francisco (US)
- Corresponding author
- McCormick, Frank
- Venue
- Nature Cancer
- Published
- 2021-03-24
- Volume
- 2
- Issue
- 3
- Pages
- 271-283
- ISSN
- 2662-1347 (ISSN-L)
- PMC
- PMC8045781
- OpenAlex
- W3138007187
- Semantic Scholar
- 8d6bdc24577b7bfea70417686ccb3aa45bcc6c18
- Cited by
- 315
- References
- 158
- Citations by year
- 2026: 27 · 2025: 48 · 2024: 81 · 2023: 73 · 2022: 56 · 2021: 30
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Frederick National Laboratory for Cancer Research (HHSN261200800001E)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- RAS-driven cancers, KRAS mutation, oncogenic Ras, tumor metabolic reprogramming, cancer metabolism, metabolic vulnerability, metabolic cancer therapy, Ras signaling
- MeSH terms
- Biology, Humans, Neoplasms, Genes, ras, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
